U.S. Serial No.: To be assigned (371 Nat'l Entry of PCT/US03/10976)
Preliminary Amendment Filed 10/12/2004

IN THE CLAIMS

Please amend the claims as follows:

- 1. (PREVIOUSLY PRESENTED) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100Da to 800 kDa.
- 2. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein the polymer has a molecular weight no greater than 60 kDa.
- 3. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
- 4. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
- 5. (PREVIOUSLY PRESENTED) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
- 6. (PREVIOUSLY PRESENTED) The composition of claim 1, further comprising a targeting ligand.

U.S. Serial No.: To be assigned

(371 Nat'l Entry of PCT/US03/10976) Preliminary Amendment Filed 10/12/2004

7. (PREVIOUSLY PRESENTED) The composition of claim 4, comprising the structure:

wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

- 8. (CURRENTLY AMENDED) A method of treating an angiogenic disease comprising administering a composition of elaims claim 1 -7 to a mammal in need thereof.
- 9. (PREVIOUSLY PRESENTED) The method of claim 8, wherein angiogenic disease is a solid tumor.

U.S. Serial No.: To be assigned (371 Nat'l Entry of PCT/US03/10976)
Preliminary Amendment Filed 10/12/2004

- 10. (PREVIOUSLY PRESENTED) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is water soluble and has a molecular weight in the range of 100 Da to 800 kDa.
- 11. (CURRENTLY AMENDMED) The composition method of claim ± 10, wherein the polymer has a molecular weight no greater than 60 kDa.
- 12. (CURRENTLY AMENDMED) The emposition method of claim ± 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
- 13. (PREVIOUSLY PRESENTED) The method of claim 10, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
- 14 (PREVIOUSLY PRESENTED) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.

U.S. Serial No.: To be assigned (371 Nat'l Entry of PCT/US03/10976)

Preliminary Amendment Filed 10/12/2004

15. (PREVIOUSLY PRESENTED) The method of claim 10, comprising the structure:

wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

- 16. The method of claim 15, wherein y is 5-10 and x is 90-95.
- 17. An HPMA-TNP-470 conjugate comprising the structure:

U.S. Serial No.: To be assigned (371 Nat'l Entry of PCT/US03/10976) Preliminary Amendment Filed 10/12/2004

*
$$\begin{array}{c|c} CH_3 \\ + CH_2 \\ CO \\ NH \\ CH_2 \\ CHOH \\ CH_3 \end{array}$$
 $\begin{array}{c|c} CH_2 \\ CH_2 \\ CO \\ NH \\ HC - C \\ H_2 \\ CO \\ NH \\ HC - C - C \\ H_2 \\ CO \\ NH \\ CH_2 \\ CO \\ CH_2 \\ CO \\ CH_2 \\ CH_3 \\$

Wherein x is 90-95 and y is 5-10.